The big pharma company's top drug is losing ground, but its dividend keeps rising.Shares of Big Pharma company AbbVie (ABBV 0.33%) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on the stock from $180 to $214 per share on Friday, July 19.Bullishness for AbbVie might seem foolhardy to the casual observer. The company's lead drug, Humira, finally lost patent-protected exclusivity in the U.S. market last year, a ...